{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T18:09:55Z","timestamp":1759601395117},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"vor","delay-in-days":6136,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2003,3]]},"DOI":"10.1093\/annonc\/mdg109","type":"journal-article","created":{"date-parts":[[2003,2,21]],"date-time":"2003-02-21T23:55:37Z","timestamp":1045871737000},"page":"388-394","source":"Crossref","is-referenced-by-count":35,"title":["Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer"],"prefix":"10.1016","volume":"14","author":[{"given":"G.P.","family":"Stathopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.K.","family":"Rigatos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Giannakakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Foutzilas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kouroussis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Janninis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Aravantinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Androulakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Agelaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.G.","family":"Stathopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Georgoulias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 6","key":"10.1093\/annonc\/mdg109_bb0010","first-page":"49","article-title":"The role of chemotherapy in the management of gastric and pancreatic carcinomas","volume":"12","author":"Schein","year":"1985","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdg109_bb0015","first-page":"220","article-title":"Chemotherapy of adenocarcinoma of the pancreas","volume":"23","author":"Schnall","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdg109_bb0020","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0305-7372(75)80003-X","article-title":"The integration of chemotherapy into a combined modality approach for cancer treatment","volume":"2","author":"Carter","year":"1975","journal-title":"VI. Pancreatic adenocarcinoma. Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdg109_bb0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/1097-0142(197807)42:1<19::AID-CNCR2820420103>3.0.CO;2-4","article-title":"Randomized phase II trial of adriamycin, methotrexate and actinomycin-D in advanced measurable pancreatic carcinoma","volume":"42","author":"Schein","year":"1978","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdg109_bb0030","first-page":"2049","article-title":"Treatment of metastatic pancreatic and gastric adenocarcinoma with 5-FU, adriamycin and mitomycin (FAM)","volume":"83","author":"Bitran","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1093\/annonc\/mdg109_bb0035","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/1097-0142(197802)41:2<387::AID-CNCR2820410201>3.0.CO;2-X","article-title":"Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer","volume":"41","author":"Wiggans","year":"1978","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdg109_bb0040","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4","article-title":"Therapy of locally unresectable pancreatic carcinomas: a randomized comparison of high dose (6000 Rads) radiation alone, moderate dose radiation (4000 Rads + 5-fluorouracil) and high dose radiation + 5-fluorouracil. The Gastrointestinal Tumor Study Group","volume":"48","author":"Moertel","year":"1981","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdg109_bb0045","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.1999.17.2.585","article-title":"Phase I\u2013II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer","volume":"17","author":"Hidalgo","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg109_bb0050","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg109_bb0055","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1023\/A:1008286908930","article-title":"Phase I trial of paclitaxel and gemcitabine administered every 2 weeks in patients with refractory solid tumors","volume":"9","author":"Rothenberg","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg109_bb0060","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1200\/JCO.1999.17.6.1779","article-title":"Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study","volume":"17","author":"Androulakis","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg109_bb0065","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1023\/A:1008310106171","article-title":"Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer","volume":"12","author":"Stathopoulos","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg109_bb0070","first-page":"98","article-title":"Evaluation of gemcitabine and irinotecan (CPT-11) as single agents and combination in solid tumors using an ex-vivo ATP assay","volume":"20","author":"Schwartz","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg109_bb0075","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/oxfordjournals.annonc.a059107","article-title":"Phase II trial of CPT-11 in patients with advanced pancreatic cancer. An EORTC Early Clinical Trials Group study","volume":"6","author":"Wagener","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg109_bb0080","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s002800100360","article-title":"A phase II study of 9-nitro-camptothecin in patients with advanced pancreatic adenocarcinoma","volume":"48","author":"Kostandoulakis","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdg109_bb0085","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdg109_bb0090","series-title":"Clinical Oncology","first-page":"201","article-title":"Response criteria","author":"Donehower","year":"1995"},{"key":"10.1093\/annonc\/mdg109_bb0095","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00873232","article-title":"Phase II trial of gemcitabine (2,2\u2032-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas","volume":"12","author":"Casper","year":"1994","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdg109_bb0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/bjc.1996.18","article-title":"Phase II study of gemcitabine in patients with advanced pancreatic cancer","volume":"73","author":"Carmichael","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdg109_bb0105","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF00873143","article-title":"Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas","volume":"13","author":"Scher","year":"1996","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdg109_bb0110","first-page":"155a","article-title":"Irinotecan combined with gemcitabine, 5-FU (5-fluorouracil), LV (leucovorin) and cisplatin (G-FLIP) is an effective and non-crossresistant regimen for refractory metastatic adenocarcinoma of the exocrine pancreas. Metastatic pancreatic cancer (MPAC)","volume":"20","author":"Bruckuer","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg109_bb0115","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.20.5.1182","article-title":"Irinotecan plus gemcitabine reduces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer","volume":"20","author":"Max","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg109_bb0120","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1023\/A:1026595525977","article-title":"Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer","volume":"11","author":"Heinemann","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg109_bb0125","first-page":"250a","article-title":"Randomized trial of gemcitabine alone or with cisplatin in advanced pancreatic cancer: a phase II multicenter study of the Southern Italy Oncology Group","volume":"18","author":"Colucci","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg109_bb0130","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/annonc\/mdf062","article-title":"Gemcitabine and oxaliplatin for patients with advanced or pancreatic metastatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study","volume":"13","author":"Alberts","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg109_bb0135","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1023\/A:1012522120294","article-title":"A phase II study evaluating tolerability and efficacy of Caelyx (liposomal doxorubicin Doxil) in the treatment of unresectable pancreatic carcinoma","volume":"12","author":"Halford","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg109_bb0140","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1023\/A:1011140818150","article-title":"Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks","volume":"12","author":"Alberts","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg109_bb0145","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.2002.11.149","article-title":"Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297","volume":"20","author":"Berlin","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg109_bb0150","first-page":"125a","article-title":"Docetaxel\/gemcitabine or docetaxel\/cisplatin in advanced pancreatic carcinoma: a randomized phase II study of the EORTC-GI group","volume":"21","author":"Lutz","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg109_bb0155","first-page":"154a","article-title":"Gemcitabine (GEM) alone or in combination with 5-FU continuous infusion (CI) in the treatment of advanced pancreatic Cancer (APC): a GOIRC randomized phase II trial","volume":"20","author":"Di Costanzo","year":"2001","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419478381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419478381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/14\/3\/388\/556314\/mdg109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T18:14:44Z","timestamp":1584468884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419478381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["S0923753419478381"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdg109","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2003,3]]}}}